title: Phase I study of intracarotid administration of carboplatin.
abstract: Fifteen patients were treated in a Phase I study of intracarotid carboplatin (200-400 mg/m2) in 5% dextrose and water infused over 15 to 30 minutes through a transfemoral catheter with a 0.2-micron inline filter. This study was done because intravenous carboplatin has less neurotoxicity than cisplatin and is active against brain tumors. Eleven men and four women ranging in age from 37 to 72 years (median, 59 years) were treated. The Eastern Cooperative Oncology Group performance status was 1 in 3, 2 in 4, and 3-4 in 8 patients. Eight patients had one to three previous chemotherapy regimens; previous radiotherapy had failed in 13 patients. The response of patients in the Phase I study follows: glioblastoma, 6 failed; not evaluated because of early death from pulmonary embolus, 1; recurrent Grade II and III glioma, 1 stable (minor response with neurologic improvement) and 2 failed; malignant oligodendroglioma, 1 failed; brain metastases from nonsmall cell lung cancer, 1 partial remission, 1 stable (minor response), and 1 failed; brain metastases from unknown primary, 1 stable (minor response with neurological improvement). Median survival was 9 weeks. Nausea was mild to moderate. One patient had granulocytopenia, and 2 had thrombocytopenia (mild). At 200 mg/m2 (2 patients), 1 had a focal seizure. At 300 mg/m2 (9 patients), 2 with abnormally small arteries had severe pain early in the treatment and posttreatment ipsilateral conjunctival edema, decreased vision, and cerebral edema (with partially reversible increased hemiparesis); 1 other had mild decrease in ipsilateral vision and 1 had transient aphasia on removal of the catheter (possibly the result of a vascular spasm).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Ontario Cancer Treatment and Research Foundation Ottawa Regional Cancer Centre, Canada.
authors.forename: D J
authors.initials: DJ
authors.lastname: Stewart
authors.forename: J M
authors.initials: JM
authors.lastname: Belanger
authors.forename: Z
authors.initials: Z
authors.lastname: Grahovac
authors.forename: S
authors.initials: S
authors.lastname: Curuvija
authors.forename: L R
authors.initials: LR
authors.lastname: Gionet
authors.forename: S E
authors.initials: SE
authors.lastname: Aitken
authors.forename: H
authors.initials: H
authors.lastname: Hugenholtz
authors.forename: B G
authors.initials: BG
authors.lastname: Benoit
authors.forename: V F
authors.initials: VF
authors.lastname: DaSilva
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016190:Carboplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000628:therapy; D002343:Carotid Artery, Internal; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D006801:Humans; D007269:Injections, Intra-Arterial; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D016190:Carboplatin